Lymphopenia is detrimental to therapeutic approaches to type 1 diabetes using regulatory T cells

Immunologic Research

Volumn 58, Issue 1, 2014, Pages 101-105

  Ash, Shifra ^a   Yarkoni, Shai ^a   Askenasy, Nadir ^a  

^a Center for Stem Cell Research   (Israel)

Author keywords

Caspase 3; Fas ligand; Fusion proteins; Immunomodulation; Interleukin 2; Lymphopenia; Regulatory T cells; Type 1 diabetes

Indexed keywords

CASPASE 3; CHIMERIC PROTEIN; CYCLOPHOSPHAMIDE; FAS LIGAND; GLUCOSE; HYBRID PROTEIN; INTERLEUKIN 2; RAPAMYCIN; STREPTAVIDIN;

ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL DEATH; CELL EXPANSION; CELL THERAPY; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMMUNITY; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; LYMPHOCYTOPENIA; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; UPREGULATION;

ANIMALS; CASPASE 3; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOMODULATION; INTERLEUKIN-2; LYMPHOPENIA; MICE, INBRED NOD; T-LYMPHOCYTES, REGULATORY;

EID: 84893754485     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8476-x     Document Type: Article

References (30)

1. Bayer AL, Pugliese A, Malek TR. The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation. Immunol Res. 2013. doi: 10.1007/s12026-013-8452-5.
2. Pugliese A. The multiple origins of Type 1 diabetes. Diabet Med. 2013;30(2):135-46.
3. Askenasy EM, Askenasy N. Is autoimmune diabetes caused by aberrant immune activity or defective suppression of physiological self-reactivity? Autoimmun Rev. 2013;12(5):633-7.
4. Kaminitz A, Stein J, Yaniv I, Askenasy N. The vicious cycle of apoptotic beta-cell death in type 1 diabetes. Immunol Cell Biol. 2007;85(8):582-9.
5. Kaminitz A, Mizrahi K, Askenasy N. Surge in regulatory cells does not prevent onset of hyperglycemia in NOD mice: immune profiles do not correlate with disease severity. Autoimmunity. 2013. doi: 10.3109/08916934.2013.866103.
6. Marek-Trzonkowska N, Mysliwec M, Siebert J, Trzonkowski P. Clinical application of regulatory T cells in type 1 diabetes. Pediatr Diabetes. 2013;14(5):322-32.
7. von Herrath M, Peakman M, Roep B. Progress in immune-based therapies for type 1 diabetes. Clin Exp Immunol. 2013;172(2):186-202.
8. Askenasy N. Hematopoietic transplants for disease suppression and cure in type 1 diabetes. Cur Stem Cell Res Ther. 2013;8(4):333-9.
9. Askenasy EM, Askenasy N, Askenasy JJ. Does lymphopenia preclude restoration of immune homeostasis? The particular case of type 1 diabetes. Autoimmun Rev. 2010;9(10):687-90.
10. Yaniv I, Ash S, Farkas DL, Askenasy N, Stein J. Consideration of strategies for hematopoietic cell transplantation. J Autoimmun. 2009;33(3-4):255-9.
11. Kaminitz A, Mizrahi K, Yaniv I, Farkas DL, Stein J, Askenasy N. Low levels of allogeneic but not syngeneic hematopoietic chimerism reverse autoimmune insulitis in prediabetic NOD mice. J Autoimmun. 2009;33(2):83-91.
12. Kaminitz A, Mizrahi M, Yaniv I, Stein J, Askenasy N. Immunosuppressive therapy exacerbates autoimmunity in NOD mice and diminishes the protective activity of regulatory T cells. J Autoimmun. 2010;35(2):145-52.
13. Yolcu ES, Kaminitz A, Ash S, Sagiv Y, Askenasy N, Yarkoni S. Apoptosis as a mechanism of T regulatory cell homeostasis and suppression. Immunol Cell Biol. 2008;86(8):650-8.
14. Bayer AL, Jones M, Chirinos J, de Armas L, Schreiber TH, Malek TR, Levy RB. Host CD4+ CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT. Blood. 2009;113(3):733-43.
15. Adeegbe D, Bayer AL, Levy RB, Malek TR. Cutting edge: allogeneic CD4+ CD25+ Foxp3+ T regulatory cells suppress autoimmunity while establishing transplantation tolerance. J Immunol. 2006;176(12):7149-53.
16. Yarkoni S, Kaminitz A, Sagiv Y, Yaniv I, Askenasy N. Involvement of IL-2 in homeostasis of regulatory T cells: the IL-2 cycle. BioEssays. 2008;30(9):875-88.
17. Malek TR. The biology of interleukin-2. Annu Rev Immunol. 2008;26:453-79.
18. Hulme MA, Wasserfall CH, Atkinson MA, Brusko TM. Central role for interleukin-2 in type 1 diabetes. Diabetes. 2012;61(1):14-22.
19. Bayer AL, Chirinos J, Cabello C, Yang J, Matsutani T, Malek TR, Levy RB. Expansion of a restricted residual host T reg-cell repertoire is dependent on IL-2 following experimental autologous hematopoietic stem transplantation. Eur J Immunol. 2011;41(12):3467-78.
20. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004;4(9):665-74.
21. Daniel C, von Boehmer H. Extrathymic generation of regulatory T cells - chances and challenges for prevention of autoimmune disease. Adv Immunol. 2011;112:177-213.
22. Putnam AL, Vendrame F, Dotta F, Gottlieb PA. CD4+ CD25high regulatory T cells in human autoimmune diabetes. J Autoimmun. 2005;24(1):55-62.
23. von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol. 2007;7(12):988-94.
24. Askenasy N, Kaminitz A, Yarkoni S. Mechanisms of T regulatory cell function. Autoimmun Rev. 2008;7(5):370-5.
25. Askenasy N. Enhanced killing activity of regulatory T cells ameliorates inflammation and autoimmunity. Autoimmun Rev. 2013;12(10):972-5.
26. Kaminitz A, Yolcu ES, Stein J, Yaniv I, Shirwan H, Askenasy N. Killer Treg restore immune homeostasis and suppress autoimmune diabetes in prediabetic NOD mice. J Autoimmun. 2011;37(1):39-47.
27. Kaminitz A, Yolcu ES, Mizrahi K, Shirwan H, Askenasy N. Killer regulatory T cells ameliorate inflammatory insulitis in diabetic NOD mice through local and systemic immunomodulation. Int Immunol. 2013;25(8):485-94.
28. Yarkoni S, Sagiv Y, Kaminitz A, Farkas DL, Askenasy N. Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis. Eur J Immunol. 2009;39(10):2850-64.
29. Yarkoni S, Kaminitz A, Sagiv Y, Yaniv I, Askenasy N. Targeting of IL-2 receptor with a caspase fusion protein disrupts autoimmunity in prediabetic and diabetic NOD mice. Diabetologia. 2010;53(2):356-68.
30. Yarkoni S, Prigozhina TB, Slavin S, Askenasy N. IL-2 targeted therapy ameliorates the severity of graft versus host disease: ex vivo selective depletion of host-reactive T cells and in vivo therapy. Biol Blood Marrow Transplant. 2012;18(4):523-35.